Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02425969
Other study ID # GzFFR Protocol Version 2.1
Secondary ID
Status Completed
Phase N/A
First received March 30, 2015
Last updated March 2, 2017
Start date April 2015
Est. completion date October 1, 2016

Study information

Verified date March 2015
Source Golden Jubilee National Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In this randomised controlled trial of patients with stable angina and documented intermediate coronary disease with indeterminate or "grey-zone" Fractional Flow Reserve (FFR) we will randomise patients to either optimal medical therapy alone versus optimal medical therapy with PCI and they will be followed up for the primary endpoint of anginal control as measured by the Seattle Angina Questionnaire at 3 months.


Description:

Pressure derived fractional flow reserve (FFR) is recognised as being the gold standard method of assessing the physiological significance of angiographically intermediate lesions. A grey-zone exists between the originally validated cut-off for ischemia of <0.75 and the conventionally adopted cut- off of ≤0.80. Pilot data from our centre has suggested that only 1 in 3 coronary arteries with grey-zone FFR values demonstrate myocardial perfusion defects on stress cardiac MRI and others have suggested that the clinical outcomes in patients with grey-zone FFR are favorable with medical therapy alone. As such, stenting all lesions with grey-zone FFR (as currently recommended) may represent over-treatment and could attenuate the overall benefit of an FFR strategy. In addition to this there are flow derived resistance indices of stenosis severity that have superior diagnostic accuracy and may be helpful in correctly classifying patients with grey-zone FFR. In this study we will a comprehensive analysis of lesions with grey-zone FFR values (0.75-0.82 inclusive) using invasive hyperemic pressure, flow and resistance derived indices of severity with quantitative and qualitative 3T perfusion MRI to enable identification of the best invasive predictors of true perfusion defects on 3T cardiac MRI. Patients will be randomised to optimal medical therapy alone versus optimal medical therapy with PCI and followed up for the primary endpoint of anginal control as measured by the Seattle Angina Questionnaire at 3 months.


Recruitment information / eligibility

Status Completed
Enrollment 108
Est. completion date October 1, 2016
Est. primary completion date October 1, 2016
Accepts healthy volunteers No
Gender All
Age group 18 Years to 90 Years
Eligibility Inclusion Criteria:

1. Patients >18 years

2. 30-80% Diameter Stenosis on QCA

3. Stable angina

4. Non ST-elevation myocardial infarction (NSTEMI) with stable symptoms

5. Able to provide informed consent

Exclusion Criteria:

1. STEMI within 5 days

2. Tortuous vessels which would render pressure wire studies difficult or impossible

3. Heavily calcified vessels which would render pressure wire studies difficult or impossible

4. Unstable symptoms requiring definitive interventional management

5. Severe claustrophobia

6. Age >90 years

7. Life expectancy <1 year

8. Estimated Glomerular Filtration Rate <30 mls/min/1.73m2

9. Inability to undergo MRI scanning due to metallic implant or incompatible permanent pacemaker

10. Severe asthma or inability to safely receive an adenosine infusion

11. Left mainstem disease =50% or if considered clinically significant by the operating cardiologist either on angiography or intravascular ultrasound.

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
PCI
Patients will have balloon angioplasty and coronary stent insertion for their grey-zone FFR lesion.
Drug:
Optimal Medical Therapy
Optimal Medical therapy consists of secondary prevention which will include high dose statin and aspirin as well as anti-anginal therapy according to ESC 2013 international treatment guidelines for stable angina as follows; B-Blocker or Calcium channel blocker as first line agents and Nicorandil or Nitrates or Ranolazine as second line treatment titrated against symptoms to maximum tolerated dose. ACE inhibitors or Angiotensin Receptor Blockers will be prescribed if patients also have a diagnosis of hypertension, LVEF =40%, diabetes or CKD where appropriate.

Locations

Country Name City State
United Kingdom Golden Jubilee National Hospital Glasgow Dunbartonshire

Sponsors (3)

Lead Sponsor Collaborator
Golden Jubilee National Hospital British Heart Foundation, University of Glasgow

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Angina status as per Seattle Angina Questionnaire Anginal severity as measured by the Seattle Angina Score at 3 months compared with baseline in patients randomized to PCI versus medical therapy. 3 months
Secondary MACE MACE (Death, myocardial infarction, urgent revascularisation and stroke) in patients randomized to PCI versus medical therapy. 3 and 12 months
Secondary Myocardial infarction Myocardial infarction in patients randomized to PCI versus medical therapy. 3 and 12 months
Secondary Urgent Revascularisation Urgent Revascularisation of the grey-zone FFR lesion in patients randomized to PCI versus medical therapy. 3 and 12 months
Secondary Total number of anti-anginal medications Total number of anti-anginal medications in patients randomized to PCI versus medical therapy. 3 and 12 months
See also
  Status Clinical Trial Phase
Active, not recruiting NCT02892903 - In the Management of Coronary Artery Disease, Does Routine Pressure Wire Assessment at the Time of Coronary Angiography Affect Management Strategy, Hospital Costs and Outcomes? N/A
Not yet recruiting NCT02871622 - BMX Alpha Registry: a Post-market Registry of the BioMatrix Alpha TM N/A
Not yet recruiting NCT02550301 - Does Mean Platelet Volume Change With Clopidogrel N/A
Completed NCT02252406 - Impact of Ranolazine in Blood Markers in Women With Angina and Metabolic Syndrome Phase 4
Active, not recruiting NCT02244853 - Heart Rate and Cardiovascular Diseases Prognosis in People With Stable Coronary Artery Disease N/A
Completed NCT01826552 - Comparison of the Angiographic Result of the Orsiro Hybrid Stent With Resolute Integrity Stent Phase 4
Not yet recruiting NCT01162902 - Comparison of Vascular Remodeling Between Different Antianginal Medication Evaluated by Noninvasive ECG-gated Fundus Photographic Evaluation Phase 4
Completed NCT02126150 - United Coronary Biobanks N/A
Completed NCT01769079 - Clinical Impact of the Withdrawal of Nitrate in Patients With Stable Angina Phase 4
Completed NCT01328470 - Effect of Platelet Inhibition According to Clopidogrel Dose in Patients With Chronic Kidney Disease Phase 4
Unknown status NCT00751491 - Clopidogrel Versus Adenosin in Non Urgent Percutaneous Coronary Intervention (PCI) Phase 3
Completed NCT00263263 - RRISC Study: Reduction of Restenosis In Saphenous Vein Grafts With Cypher Sirolimus-Eluting Stent. Phase 2
Active, not recruiting NCT04929496 - Physiology as Guidance to Evaluate the Direct Impact of Coronary Lesion Treatment: The PREDICT Study N/A
Completed NCT03103620 - Safety and Effectiveness Evaluation of COBRA PzF Coronary Stent System: A Post Marketing Observational Registry
Recruiting NCT05459051 - Finding the Invasive Haemodynamic Threshold for Symptom Relief in Stable Angina
Completed NCT06464276 - Effectiveness and Tolerability of Trimetazidine 80mg Once Daily in Patients With Chronic Coronary Syndrome: The V-GOOD Study
Not yet recruiting NCT04403048 - Drug Coated Balloon for Side Branch Treatment vs. Conventional Approach in True Bifurcation Coronary Disease: PRO-DAVID N/A
Completed NCT01974492 - Comparison of Saphenous Vein Graft Harvested From Upper Versus Lower Leg in Coronary Artery Bypass Grafting N/A
Completed NCT01990924 - Low Rate Fluoroscopy to Reduce Radiation Dose During Coronary Angiography and Intervention N/A
Completed NCT02120859 - Optical Coherence Tomography to Investigate FFR-Guided DEB-only Elective Coronary Angioplasty Phase 4